News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
scanx.trade Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Cocrystal Pharma Inc is projected to report a loss of 16 cents per share. This information is part of an earnings preview. The full article is available through a TradingView subscription.
Phillip Frost, a director and 10% owner of Cocrystal Pharma, Inc. (NASDAQ:COCP), recently purchased 10,000 shares of the company's common stock for $9,816. This transaction occurred on August 5, 2026, with shares acquired at a weighted average price of $0.9816. The purchase comes after …
OPKO Health, Inc. has reported a significant ownership stake of 29.6% in Cocrystal Pharma, Inc. common stock, following a private purchase of 5,474,053 shares for $5 million. Alongside OPKO, key insiders Phillip Frost, M.D., Frost Gamma Investments Trust, and Steven D. Rubin also hold …
Phillip Frost, M.D., and Frost Gamma Investments Trust have reported an updated beneficial ownership stake in Cocrystal Pharma, Inc. (COCP), totaling 13.9% of the common stock. This includes direct holdings, shares held by the trust, and exercisable options and warrants. The filing, a Schedule …
Phillip Frost M.D., a director and 10% owner of Cocrystal Pharma, Inc. (COCP), indirectly purchased 10,000 shares of common stock on August 5, 2026, at a weighted average price of $0.9816 per share through Frost Gamma Investments Trust. Following this transaction, the trust holds …
Cocrystal Pharma Inc (COCP) has an earnings forecast score of 8.00, placing it 171st out of 387 in the Biotechnology & Medical Research industry. Analysts project an average price target of $8.00, with a high of $10.00 and a low of $6.00. Based on …
Frost Gamma Investments Trust, an entity linked to Cocrystal Pharma director Phillip Frost, M.D., recently purchased 75,000 shares of COCP common stock. The transaction occurred on August 3, 2026, at a weighted average price of $0.9412 per share. Following this acquisition, the trust indirectly …
Cocrystal Pharma (COCP) has announced a private placement deal with OPKO Health, raising $5 million by issuing 5,474,053 common shares at $0.9134 per share. The company plans to use the net proceeds to advance its preclinical and clinical drug candidate programs, as well as …
OPKO Health (NASDAQ:OPK) has invested an additional $5 million in Cocrystal Pharma (NASDAQ:COCP) by purchasing over 5.4 million shares at $0.9134 per share. This investment comes as Cocrystal Pharma advances its lead norovirus program, CDI-988, which is currently in a Phase 1b clinical trial …
This article provides a basic overview of Cocrystal Pharma, Inc. (COCP) financial information available on TradingView, specifically mentioning revenue breakdown access. It outlines various financial data points like statements, statistics, dividends, earnings, and segment performance. The page primarily functions as a navigation and informational …
This article provides a risk assessment for Cocrystal Pharma Inc (COCP), highlighting its current risk score of 3.04, which ranks it 163 out of 384 in the Biotechnology & Medical Research industry. It details the company's beta value of 1.44, indicating higher volatility than …
This article analyzes the financial health of Cocrystal Pharma Inc (COCP), noting a current financial score of 6.45, ranking it 254th out of 385 in the Biotechnology & Medical Research industry. While its financial status is robust, its operating efficiency is low. Key financial …
This article provides a valuation analysis of Cocrystal Pharma Inc (COCP) as of July 28, 2026. The company has a current valuation score of 6.36, ranking 323 out of 385 in the Biotechnology & Medical Research industry, with a P/E ratio of -1.29. Key …
This article analyzes market sentiment for Cocrystal Pharma (COCP) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from analysts, a 3.9% declining short float (bullish), and reports on recent insider stock option acquisitions by board members. …
This article provides a comprehensive stock analysis of Cocrystal Pharma Inc (COCP) by TradingKey. It highlights the company's relatively healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, analysts maintain a "Buy" …
This article from TradingKey attempts to provide a revenue breakdown for Cocrystal Pharma Inc (COCP) by business segment and region. However, it explicitly states that the relevant financial data has not been disclosed by the company yet. The page provides current stock information for …
This article details the shareholder structure of Cocrystal Pharma Inc (COCP), identifying major shareholders like Frost Gamma Investments Trust and Fred Hassan, along with institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes …
This NASDAQ page provides live quotes and charts for Cocrystal Pharma Inc. (COCP), showing its current stock price, a slight decrease, and an interactive chart. It indicates that there are no analyst ratings or earnings information currently available for the company. The page is …
Cocrystal Pharma, Inc. filed an 8-K report on July 14, 2026, detailing the results of its annual shareholder meeting. Key outcomes included the election of five directors and the ratification of Weinberg & Company as the independent auditor for the fiscal year ending December …
Cocrystal Pharma, Inc. held its 2026 Annual Meeting of Stockholders on July 14, 2026, where investors reelected all five director nominees and ratified Weinberg & Company as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The adjournment proposal …
Search by ticker symbol or company name and select a result to open its chart.